Publikationen von Harbeck, N.

Zur erweiterten Suche

Eine Ebene nach oben

Gruppiert nach: Dokumententyp | Veröffentlichungsdatum

Springe zu: Zeitschriftenartikel

Anzahl der Publikationen: 88

Zeitschriftenartikel

Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y. H.; Hui, R.; Harbeck, N.; Takahashi, M.; Untch, M.; Fasching, P. A.; Cardoso, F.; Andersen, J.; Patt, D.; Danso, M.; Ferreira, M.; Mouret-Reynier, M.-A.; Im, S.-A.; Ahn, J.-H.; Gion, M.; Baron-Hay, S.; Boileau, J.-F.; Ding, Y.; Tryfonidis, K.; Aktan, G.; Karantza, V. und O'Shaughnessy, J. (2022): Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. In: New England Journal of Medicine, Bd. 386, Nr. 6: S. 556-567

Gampenrieder, S. P.; Dezentje, V.; Lambertini, M.; de Nonneville, A.; Marhold, M.; Le Du, F.; Salgado, A. Cortes; Costa, D. Alpuim; Batista, M. Vaz; Ruche, N. Chic; Tinchon, C.; Petzer, A.; Blondeaux, E.; Del Mastro, L.; Targato, G.; Bertucci, F.; Goncalves, A.; Viret, F.; Bartsch, R.; Mannsbart, C.; Deleuze, A.; Robert, L.; Serrano, C. Saavedra; Cortes, M. Gion; Sampaio-Alves, M.; Vitorino, M.; Pecen, L.; Singer, C.; Harbeck, N.; Rinnerthaler, G. und Greil, R. (2022): Influence of HER2 expression on prognosis in metastatic triple-negative breast cancerdresults from an international, multicenter analysis coordinated by the AGMT Study Group. In: ESMO Open, Bd. 8, Nr. 1, 100747

Sessa, C.; Balmana, J.; Bober, S. L.; Cardoso, M. J.; Colombo, N.; Curigliano, G.; Domchek, S. M.; Evans, D. G.; Fischerova, D.; Harbeck, N.; Kuhl, C.; Lemley, B.; Levy-Lahad, E.; Lambertini, M.; Ledermann, J. A.; Loibl, S.; Phillips, K. -A. und Paluch-Shimon, S. (2022): Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. In: Annals of Oncology, Bd. 34, Nr. 1: S. 33-47

Paluch-Shimon, S.; Cardoso, F.; Partridge, A. H.; Abulkhair, O.; Azim, H. A.; Bianchi-Micheli, G.; Cardoso, M. J.; Curigliano, G.; Gelmon, K. A.; Gentilini, O.; Harbeck, N.; Kaufman, B.; Kim, S. B.; Liu, Q.; Merschdorf, J.; Poortmans, P.; Pruneri, G.; Senkus, E.; Sirohi, B.; Spanic, T.; Sulosaari, V.; Peccatori, F. und Pagani, O. (2022): ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). In: Annals of Oncology, Bd. 33, Nr. 11: S. 1097-1118

Trapani, D.; Franzoi, M. A.; Burstein, H. J.; Carey, L. A.; Delaloge, S.; Harbeck, N.; Hayes, D. F.; Kalinsky, K.; Pusztai, L.; Regan, M. M.; Sestak, I.; Spanic, T.; Sparano, J.; Jezdic, S.; Cherny, N.; Curigliano, G. und Andre, F. (2022): Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. In: Annals of Oncology, Bd. 33, Nr. 7: S. 702-712

Dent, S.; Cortes, J.; Im, Y.-H.; Dieras, V.; Harbeck, N.; Krop, I. E.; Wilson, T. R.; Cui, N.; Schimmoller, F.; Hsu, J. Y.; He, J.; De Laurentiis, M.; Sousa, S.; Drullinsky, P. und Jacot, W. (2021): Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. In: Annals of Oncology, Bd. 32, Nr. 2: S. 197-207

Schrodi, S.; Braun, M.; Andrulat, A.; Harbeck, N.; Mahner, S.; Kiechle, M.; Klein, E.; Schnelzer, A.; Schindlbeck, C.; Bauerfeind, I.; Schubert-Fritschle, Gabriele; Nekljudova, V.; Mayr, D.; Weichert, W.; Denkert, C.; Loibl, S. und Engel, J. (2021): Outcome of breast cancer patients with low hormone receptor positivity. Analysis of a 15-year population-based cohort. In: Annals of Oncology, Bd. 32, Nr. 11: S. 1410-1424 [PDF, 1MB]

Gennari, A.; Andre, F.; Barrios, C. H.; Cortes, J.; de Azambuja, E.; DeMichele, A.; Dent, R.; Fenlon, D.; Gligorov, J.; Hurvitz, S. A.; Im, S. -a.; Krug, D.; Kunz, W. G.; Loi, S.; Penault-Llorca, F.; Ricke, J.; Robson, M.; Rugo, H. S.; Saura, C.; Schmid, P.; Singer, C. F.; Spanic, T.; Tolaney, S. M.; Turner, N. C.; Curigliano, G.; Loibl, S.; Paluch-Shimon, S. und Harbeck, N. (2021): ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. In: Annals of Oncology, Bd. 32, Nr. 12: S. 1475-1495

Harbeck, N.; Rastogi, P.; Martin, M.; Tolaney, S. M.; Shao, Z. M.; Fasching, P. A.; Huang, C. S.; Jaliffe, G. G.; Tryakin, A.; Goetz, M. P.; Rugo, H. S.; Senkus, E.; Testa, L.; Andersson, M.; Tamura, K.; Del Mastro, L.; Steger, G. G.; Kreipe, H.; Hegg, R.; Sohn, J.; Guarneri, V.; Cortes, J.; Hamilton, E.; Andre, V.; Wei, R.; Barriga, S.; Sherwood, S.; Forrester, T.; Munoz, M.; Shahir, A.; San Antonio, B.; Nabinger, S. C.; Toi, M.; Johnston, S. R. D. und O'Shaughnessy, J. (2021): Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. In: Annals of Oncology, Bd. 32, Nr. 12: S. 1571-1581

Müller, V.; Banys-Paluchowski, M.; Friedl, T. W. P.; Fasching, P. A.; Schneeweiss, A.; Hartkopf, A.; Wallwiener, D.; Rack, B.; Meier-Stiegen, F.; Huober, J.; Rübner, M.; Hoffmann, O.; Müller, L.; Janni, W.; Wimberger, P.; Jäger, B.; Pantel, K.; Riethdorf, S.; Harbeck, N. und Fehm, T. (2021): Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. In: Esmo Open, Bd. 6, Nr. 6

Hack, C. C.; Haeberle, L.; Brucker, S. Y.; Janni, W.; Volz, B.; Loehberg, C. R.; Hartkopf, A. D.; Walter, C.-B.; Baake, G.; Fridman, A.; Malter, W.; Würstlein, R.; Harbeck, N.; Hoffmann, O.; Kuemmel, S.; Martin, B.; Thomssen, C.; Graf, H.; Wolf, C.; Lux, M. P.; Bayer, C. M.; Rauh, C.; Almstedt, K.; Gass, P.; Heindl, F.; Brodkorb, T.; Willer, L.; Lindner, C.; Kolberg, H-C; Krabisch, P.; Weigel, M.; Steinfeld-Birg, D.; Kohls, A.; Brucker, C.; Schulz, V.; Fischer, G.; Pelzer, V.; Rack, B.; Beckmann, M. W.; Fehm, T.; Rody, A.; Maass, N.; Hein, A.; Fasching, P. A. und Nabieva, N. (2020): Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. In: Breast, Bd. 50: S. 11-18

Cardoso, F.; Paluch-Shimon, S.; Senkus, E.; Curigliano, G.; Aapro, M. S.; Andre, F.; Barrios, C. H.; Bergh, J.; Bhattacharyya, G. S.; Biganzoli, L.; Boyle, F.; Cardoso, M-J; Carey, L. A.; Cortes, J.; El Saghir, N. S.; Elzayat, M.; Eniu, A.; Fallowfield, L.; Francis, P. A.; Gelmon, K.; Gligorov, J.; Haidinger, R.; Harbeck, N.; Hu, X.; Kaufman, B.; Kaur, R.; Kiely, B. E.; Kim, S.-B.; Lin, N. U.; Mertz, S. A.; Neciosup, S.; Offersen, B. V.; Ohno, S.; Pagani, O.; Prat, A.; Penault-Llorca, F.; Rugo, H. S.; Sledge, G. W.; Thomssen, C.; Vorobiof, D. A.; Wiseman, T.; Xu, B.; Norton, L.; Costa, A. und Winer, E. P. (2020): 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). In: Annals of Oncology, Bd. 31, Nr. 12: S. 1623-1649

Paluch-Shimon, S.; Cardoso, F.; Partridge, A. H.; Abulkhair, O.; Azim, H. A.; Bianchi-Micheli, G.; Cardoso, M-J; Curigliano, G.; Gelmon, K. A.; Harbeck, N.; Merschdorf, J.; Poortmans, P.; Pruneri, G.; Senkus, E.; Spanic, T.; Stearns, V.; Wengstrom, Y.; Peccatori, F. und Pagani, O. (2020): ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). In: Annals of Oncology, Bd. 31, Nr. 6: S. 674-696

Wuerstlein, R.; Kates, R.; Gluz, O.; Grischke, E. M.; Schem, C.; Thill, M.; Hasmüller, S.; Köhler, A.; Otremba, B.; Griesinger, F.; Schindlbeck, C.; Trojan, A.; Otto, F.; Knauer, M.; Pusch, R. und Harbeck, N. (2019): Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study. In: Breast Cancer Research and Treatment, Bd. 175, Nr. 2: S. 389-399

Im, S. -A.; Lu, Y. -S.; Bardia, A.; Harbeck, N.; Colleoni, M.; Franke, F.; Chow, L.; Sohn, J.; Lee, K. -S.; Campos-Gomez, S.; Villanueva-Vazquez, R.; Jung, K. -H.; Chakravartty, A.; Hughes, G.; Gounaris, I.; Rodriguez-Lorenc, K.; Taran, T.; Hurvitz, S. und Tripathy, D. (2019): Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. In: New England Journal of Medicine, Bd. 381, Nr. 4: S. 307-316

Blackwell, K.; Gascon, P.; Krendyukov, A.; Gattu, S.; Li, Y. und Harbeck, N. (2018): Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. In: Annals of Oncology, Bd. 29, Nr. 1: S. 244-249

Nabieva, N.; Kellner, S.; Fehm, T.; Häbrle, L.; Waal, J. de; Rezai, M.; Baier, B.; Baake, G.; Kolberg, H.-C.; Guggenberger, M.; Warm, M.; Harbeck, N.; Würstlein, R.; Deuker, J.-U.; Dall, P.; Richter, B.; Wachsmann, G.; Brucker, C.; Siebers, J. W.; Fersis, N.; Kuhn, T.; Wolf, C.; Vollert, H.-W.; Breitbach, G.-P.; Janni, W.; Landthaler, R.; Kohls, A.; Rezek, D.; Nösselt, T.; Fischer, G.; Henschen, S.; Prätz, T.; Heyl, V.; Kühn, T.; Krauss, T.; Thomssen, C.; Hohn, A.; esch, H.; Mundhenke, C.; Hein, A.; Rauh, C.; Bayer, C. M.; Jacob, A.; Schmidt, K.; Belleville, E.; Brucker, S. Y.; Kümmel, S.; Beckmann, M. W.; Wallwiener, D.; Hadji, P. und Fasching, P. A. (2018): Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. In: Annals of Oncology, Bd. 29, Nr. 1: S. 186-192

Rugo, H. S.; Dieras, V.; Gelmon, K. A.; Finn, R. S.; Slamon, D. J.; Martin, M.; Neven, P.; Shparyk, Y.; Mori, A.; Lu, D. R.; Bhattacharyya, H.; Bartlett, C. Huang; Iyer, S.; Johnston, S.; Ettl, J. und Harbeck, N. (2018): Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. In: Annals of Oncology, Bd. 29, Nr. 4: S. 888-894

Turner, N. C.; Slamon, D. J.; Ro, J.; Bondarenko, I; Im, S-A; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Loibl, S.; Andre, F.; Puyana Theall, K.; Huang, X.; Giorgetti, C.; Huang Bartlett, C. und Cristofanilli, M. (2018): Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. In: New England Journal of Medicine, Bd. 379, Nr. 20: S. 1926-1936

Yardley, D. A.; Coleman, R.; Conte, P.; Cortes, J.; Brufsky, A.; Shtivelband, M.; Young, R.; Bengala, C.; Ali, H.; Eakel, J.; Schneeweiss, A.; de la Cruz-Merino, L.; Wilks, S.; O'Shaughnessy, J.; Gluck, S.; Li, H.; Miller, J.; Barton, D. und Harbeck, N. (2018): nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. In: Annals of Oncology, Bd. 29, Nr. 8: S. 1763-1770

Nabieva, N.; Fehm, T.; Haeberle, L.; Waal, J. de; Rezai, M.; Baier, B.; Baake, G.; Kolberg, H. -C.; Guggenberger, M.; Warm, M.; Harbeck, N.; Würstlein, R.; Deuker, J. -U.; Dall, P.; Richter, B.; Wachsmann, G.; Brucker, C.; Siebers, J. W.; Popovic, M.; Kuhn, T.; Wolf, C.; Vollert, H. -W.; Breitbach, G. -P.; Janni, W.; Landthaler, R.; Kohls, A.; Rezek, D.; Noesselt, T.; Fischer, G.; Henschen, S.; Praetz, T.; Heyl, V.; Kuehn, T.; Krauss, T.; Thomssen, C.; Hohn, A.; Tesch, H.; Mundhenke, C.; Hein, A.; Hack, C. C.; Schmidt, K.; Belleville, E.; Brucker, S. Y.; Kuemmel, S.; Beckmann, M. W.; Wallwiener, D.; Hadji, P. und Fasching, P. A. (2018): Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. In: European Journal of Cancer, Bd. 96: S. 82-90

Möbus, V.; Jackisch, C.; Luck, H. J.; du Bois, A.; Thomssen, C.; Kuhn, W.; Nitz, U.; Schneeweiss, A.; Huober, J.; Harbeck, N.; Minckwitz, G. von; Runnebaum, I. B.; Hinke, A.; Konecny, G. E.; Untch, M. und Kurbacher, C. (2018): Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. In: Annals of Oncology, Bd. 29, Nr. 1: S. 178-185

Cardoso, F.; Senkus, E.; Costa, A.; Papadopoulos, E.; Aapro, M.; Andre, F.; Harbeck, N.; Aguilar Lopez, B.; Barrios, C. H.; Bergh, J.; Biganzoli, L.; Börs-Doers, C. B.; Cardoso, M. J.; Carey, L. A.; Cortes, J.; Curigliano, G.; Dieras, V.; El Saghir, N. S.; Eniu, A.; Fallowfield, L.; Francis, P. A.; Gelmon, K.; Johnston, S. R. D.; Kaufmann, B.; Koppikar, S.; Krop, I. E.; Mayer, M.; Nakigudde, G.; Offersen, B. V.; Ohno, S.; Pagani, O.; Paluch-Shimon, S.; Penault-Llorca, F.; Prat, A.; Rugo, H. S.; Sledge, G. W.; Spence, D.; Thomssen, C.; Vorobiof, D. A.; Xu, B.; Norton, L. und Winer, E. P. (2018): 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). In: Annals of Oncology, Bd. 29, Nr. 8: S. 1634-1657

Elger, T.; Decker, T.; Fehm, T.; Fuxius, S.; Harbeck, N.; Juhasz-Böss, I.; Möbus, V.; Thomssen, C.; Seehase, M.; Schollenberger, L.; Ruckes, C. und Schmidt, M. (2017): VinoMetro: Phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy. In: Annals of Oncology, Bd. 28

Krajnak, S.; Decker, T.; Fehm, T.; Fuxius, S.; Harbeck, N.; Juhasz-Böss, I.; Möbus, V.; Thomssen, C.; Seehase, M.; Schollenberger, L.; Ruckes, C. und Schmidt, M. (2017): VinoMetro: phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2-breast cancer resistant to endocrine therapy. In: Oncology Research and Treatment, Bd. 40: S. 88

Dam, P. A. van; Tomatis, M.; Marotti, L.; Heil, J.; Mansel, R. E.; Turco, M. Rosselli del; Dam, P. J. van; Casella, D.; Bassani, L. G.; Danei, M.; Denk, A.; Egle, D.; Emons, G.; Friedrichs, K.; Harbeck, N.; Kiechle, M.; Kimmig, R.; Köhler, U.; Kümmel, S.; Maass, N.; Mayr, C.; Prove, A.; Rageth, C.; Regolo, L.; Lorenz-Salehi, F.; Sarlos, D.; Singer, C.; Sohn, C.; Staelens, G.; Tinterri, C.; Audisio, R. und Ponti, A. (2017): Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres. In: European Journal of Cancer, Bd. 85: S. 15-22

Mittendorf, E. A.; Barrios, C. H.; Harbeck, N.; Jung, K. H.; Miles, D.; Saji, S.; Zhang, H.; Duc, A-N.; Rafii, S. und Lai, C. (2017): IMpassion031: A phase III study comparing neoadjuvant atezolizumab (atezo) vs placebo in combination with anthracycline/nab- paclitaxel (nab-pac)-based chemotherapy in early triple-negative breast cancer (eTNBC). In: Annals of Oncology, Bd. 28

Duffy, M. J.; Harbeck, N.; Nap, M.; Molina, R.; Nicolini, A.; Senkus, E. und Cardoso, F. (2017): Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). In: European Journal of Cancer, Bd. 75: S. 284-298

Gerland, L.; Frisse, S.; Latta, S.; Bloch, W.; Harbeck, N. und Baumann, F. T. (2017): Evaluation of the implementation of training control in a three-month high-intensity resistance training intervention with breast cancer patients undergoing chemotherapy. In: Oncology Research and Treatment, Bd. 40: S. 260

Gennari, A.; Brain, E.; Nanni, O.; Couselo, E. Munoz; Harbeck, N.; Geiss, R.; Rocca, A.; Cortes, J.; Degenhardt, T.; Piccardo, A.; Alberini, J-L.; Matteucci, F.; Decensi, A.; Corradengo, D. S.; Andreis, D.; Marra, D.; Gebhart, G.; Brambati, C.; Amadori, D. und Bruzzi, P. (2017): Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intrapatient heterogeneity in metastatic breast cancer (MBC): A European TRANSCAN program. In: Annals of Oncology, Bd. 28

Corradini, S.; Schönecker, S.; Pazos, M.; Freislederer, P.; Reitz, D.; Ditsch, N.; Bodungen, V. von; Würstlein, R.; Harbeck, N. und Belka, C. (2017): DIBH radiotherapy in left-sided breast cancer patients using an optical surface scanning system. In: Breast, Bd. 32: S70-S71

Gluz, O.; Nitz, U.; Christgen, M.; Kates, R.; Clemens, M.; Nuding, B.; Shak, S.; Würstlein, R.; Kreipe, H. und Harbeck, N. (2017): Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2-early breast cancer (EBC) patients with 1-3 involved lymph nodes. In: Breast, Bd. 32: S93-S93

Harbeck, N. (2017): Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer. In: Breast, Bd. 32: S18-S18

Mamounas, E. P.; Goldstein, L. J.; Penault-Llorca, F.; Roché, H.; Gluz, O.; Harbeck, N.; Nitz, U.; O'Shaughnessy, J. und Albain, K. S. (2017): Chemotherapy (CT) decision in node-positive (N plus ), ER plus , early breast cancer (EBC) after new ASCO Guideline - evidence for the 21-gene Recurrence Score (RS) assay. In: Breast, Bd. 32: S98-S98

Würstlein, R.; Grischke, E. M.; Gluz, O.; Kates, R.; Persoon, M.; Thill, M.; Hasmüller, S.; Knauer, M.; Pusch, R. und Harbeck, N. (2017): Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results. In: Breast, Bd. 32: S107-S107

Mitra, D.; Kurosky, S.; Kaye, J. und Harbeck, N. (2017): Treatment patterns and clinical outcomes in ER+/HER2-metastatic breast cancer in German real world settings. In: European Journal of Cancer, Bd. 72: S141-S141

Brain, E.; Corradengo, D.; Oriana, N.; Piccardo, A.; Matteucci, F.; Cortes, J.; Harbeck, N.; Würstlein, R.; Piris, A.; Alberini, J.-L.; Merlo, D. F.; Degenhardt, T.; Turbiez, I.; Madar, O.; Monti, M.; Cesaro, A.; Rivitti, E.; Rollandi, G. A.; Iacozzi, M.; Campazzi, E.; Campora, S.; Camporese, D. und Gennari, A. (2017): Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011. In: Cancer Research, Bd. 77

Harbeck, N.; Nitz, U. A.; Matthias, C.; Kates, R.; Braun, M.; Kümmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Grischke, E.-M.; Haas, S. L. de; Deurloo, R.; Schumacher, J.; Würstlein, R.; Kreipe, H. H. und Gluz, O. (2017): The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 +/- endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC). In: Cancer Research, Bd. 77

Mamounas, E.; Goldstein, L.; Penault-Llorca, F.; Roche, H.; Gluz, O.; Harbeck, N.; Nitz, U.; O'Shaughnessy, J. und Albain, K. (2017): Chemotherapy (CT) decision in patients (pts) with node-positive (N plus ), ER plus , early breast cancer (EBC) in the wake of new ASCO guideline - A different take on the evidence for the 21-gene recurrence score (RS) assay. In: Cancer Research, Bd. 77

Prat, A.; Ortega, V.; Villagrasa, P.; Paré, L.; Galván, P.; Oliveira, M.; Nucíforo, P.; Lluch, A.; Morales, S.; Amillano, K.; Lopez, R.; Gonzalez, R.; Manso, L.; Martinez, J.; Llombart, A.; Peña, L. de la; Cosimo, S. di; Rubio, I. T.; Harbeck, N.; Baselga, J. und Cortés, J. (2017): Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer. In: Cancer Research, Bd. 77

Yardley, D.; Coleman, R.; Conte, P.; Cortes, J.; Brufsky, A.; Shtivelband, M.; Young, R.; Bengala, C.; Ali, H.; Eakel, J.; Schneeweiss, A.; Cruz Merino, L. de la; Wilks, S.; O'Shaugnessy, J.; Glück, S.; Li, H.; Beck, R.; Barton, D. und Harbeck, N. (2017): nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial. In: Cancer Research, Bd. 77

Cardoso, F.; Harbeck, N.; Barrios, C. H.; Bergh, J.; Cortés, J.; El Saghir, N.; Francis, P. A.; Hudis, C. A.; Ohno, S.; Partridge, A. H.; Sledge, G. W.; Smith, I. E. und Gelmon, K. A. (2017): Research needs in breast cancer. In: Annals of Oncology, Bd. 28, Nr. 2: S. 208-217

Shi, W.; Jiang, T.; Nuciforo, P.; Hatzis, C.; Holmes, E.; Harbeck, N.; Sotiriou, C.; Peña, L.; Loi, S.; Rosa, D. D.; Chia, S.; Wardley, A.; Ueno, T.; Rossari, J.; Eidtmann, H.; Armour, A.; Piccart-Gebhart, M.; Rimm, D. L.; Baselga, J. und Pusztai, L. (2017): Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. In: Annals of Oncology, Bd. 28, Nr. 1: S. 128-135

Dieras, V.; Harbeck, N.; Joy, A. A.; Gelmon, K. A.; Ettl, J.; Verma, S.; Lu, D.; Gauthier, E. R.; Schnell, P.; Mori, A.; Rugo, H. S. und Finn, R. S. (2017): PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) first-line advanced breast cancer (ABC) receiving palbociclib plus letrozole (P plus L). In: Annals of Oncology, Bd. 28

Gluz, O.; Nitz, U.; Christgen, M.; Malter, W.; Clemens, M.; Reimer, T.; Nuding, B.; Aktas, B.; Stefek, A.; Ppllmanns, A.; Lorenz-Salehi, F.; Uleer, C.; Krabisch, P.; Kümmel, S.; Liedtke, C.; Shak, S.; Kates, R.; Würstlein, R.; Kreipe, H. H. und Harbeck, N. (2017): Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2-early breast cancer (EBC): WSG PlanB trial results. In: Annals of Oncology, Bd. 28

Nitz, U.; Gluz, O.; Huober, J.; Kreipe, H. H.; Kates, R. E.; Hartmann, A.; Erber, R.; Moustafa, Z.; Scholz, M.; Lisboa, B.; Mohrmann, S.; Möbus, V.; Augustin, D.; Hoffmann, G.; Weiss, E.; Böhmer, S.; Kreienberg, R.; Bois, A. du; Sattler, D.; Thomssen, C.; Kiechle, M.; Jänicke, F.; Wallwiener, D.; Harbeck, N. und Kuhn, W. (2017): Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014). In: Annals of Oncology, Bd. 28, Nr. 11: S. 2899

Nitz, U. A.; Gluz, O.; Christgen, M.; Grischke, E.-M.; Augustin, D.; Kümmel, S.; Braun, M.; Potenberg, J.; Kohls, A.; Krauss, K.; Stefek, A.; Schumacher, C.; Forstbauer, H.; Reimer, T.; Fischer, H.; Liedtke, C.; Würstlein, R.; Schumacher, J.; Kates, R.; Kreipe, H. und Harbeck, N. (2017): De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel. In: Annals of Oncology, Bd. 28, Nr. 11: S. 2768-2772

Wonhöfer, M.; Schindler, F.; Welslau, M.; Würstlein, R.; Harbeck, N. und Schinköthe, T. (2017): Elderly patients do benefit from eHealth support. In: Oncology Research and Treatment, Bd. 40: S. 264

Tiefenthaller, A.; Brix, N.; Escudero, Pazos M.; Kost, B.; Rack, B.; Bodungen, V. von; Weissenbacher, T.; Würstlein, R.; Rühle, P.; Gaipl, U.; Harbeck, N.; Belka, C.; Scheithauer, H. und Lauber, K. (2017): Immunologische Aspekte der intraoperativen Radiotherapie beim Mammakarzinom nach brusterhaltender Operation. In: Strahlentherapie und Onkologie, Bd. 193: S72-S72

Würstlein, R.; Gluz, O.; Kates, R.; Persoon, M.; Wasmayr, M.; Knauer, M.; Koplmüller, R.; Grischke, E.-M.; Schem, C.; Thill, M.; Hasmüller, S.; Griesinger, F.; Köhler, A.; Otremba, B.; Schindlbeck, C.; Reimer, T.; Krauter, J.; Tome, O.; Otto, F.; Friedrichs, K.; Albert, U.-S.; Gebauer, G.; Nitz, U. und Harbeck, N. (2017): Results of multigene assay (MammaPrint (R)) and molecular subtyping (BluePrint (R)) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study. In: Cancer Research, Bd. 77

Blackwell, K.; Gascon, P.; Jones, C. M.; Nixon, A.; Krendyukov, A.; Nakov, R.; Li, Y. und Harbeck, N. (2017): Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. In: Annals of Oncology, Bd. 28, Nr. 9: S. 2272-2277

Harbeck, N. (2016): 50 Jahre Fortschritte in der Arzneimitteltherapie: Mammakarzinom. In: Drug Research, Bd. 66: S29-S30

Harbeck, N.; Iyer, S.; Turner, N.; Cristofanilli, M.; Ro, J.; André, F.; Loi, S.; Verma, S.; Iwata, H.; Bhattacharyya, H.; Theall, K. Puyana; Bartlett, C. H. und Loibl, S. (2016): Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. In: Annals of Oncology, Bd. 27, Nr. 6: S. 1047-1054

Untch, M.; Augustin, D.; Ettl, J.; Haidinger, R.; Harbeck, N.; Lück, H.-J.; Lüftner, D.; Marée, F.; Müller, L.; Overkamp, F.; Ruckhäberle, E.; Thill, M.; Thomssen, C.; Wuerstlein, R. und Marschner, N. (2016): ABC3 Consensus Commented from the Perspective of the German Guidelines Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07.11.2015. In: Geburtshilfe und Frauenheilkunde, Bd. 76, Nr. 2: S. 156-163

Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Sotlar, K.; Grischke, E. M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; Pelz, E.; Kates, R. E.; Wuerstlein, R.; Kreipe, H. H. und Harbeck, N. (2016): Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. In: Cancer Research, Bd. 76

Harbeck, N.; Gluz, O.; Christgen, M.; Braun, M.; Kuemmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Kates, R. E.; Wuerstlein, R.; Haas, S. L. de; Kiermaier, A.; Kreipe, H. H. und Nitz, U. (2016): Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer. In: Cancer Research, Bd. 76

Pusztai, L.; Shi, W.; Jiang, T.; Nuciforo, P.; Holmes, E.; Harbeck, N.; Sotiriou, C.; Rimm, D.; Hatzis, C.; Pena, L. de la; Armour, A.; Piccart-Gebhart, M. und Baselga, J. (2016): Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies. In: Cancer Research, Bd. 76

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Hofmann, D.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Morel, P.; Cowens, W.; Hornberger, J.; Kates, R. E.; Pelz, E. und Harbeck, N. (2016): Prosigna®(R) results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study. In: Cancer Research, Bd. 76

Verma, S.; DeMichele, A. M.; Loi, S.; Ro, J.; Colleoni, M.; Iwata, H.; Harbeck, N.; Stearns, V.; Cristofanilli, M.; Huang Bartlett, C.; Schnell, P.; Zhang, K.; Thiele, A.; Turner, N. C. und Rugo, H. S. (2016): Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. In: Cancer Research, Bd. 76

Burgmann, M.; Hermelink, K.; Farr, A.; Heiduschka, A.; Meegen, F. van; Engel, J.; Harbeck, N. und Wuerstlein, R. (2016): Cancer-specific distress, life satisfaction and parenting concerns in young breast cancer survivors. In: Cancer Research, Bd. 76

Kolben, T.; Schwarz, T. M.; Goess, C.; Blume, C.; Degenhardt, T.; Engel, J.; Wuerstlein, R.; Ditsch, N.; Harbeck, N. und Kahlert, S. (2016): Surcigal management of ipsilateral breast tumor recurrence. In: Cancer Research, Bd. 76

Prat, A.; Ortega, V.; Paré, L.; Galván, P.; Oliveira, M.; Nuciforo, P.; Lluch, A.; Morales, S.; Amillano, K.; Lopez, R.; González, R.; Manso, L.; Martínez, J.; Llombart, A.; Peña, L. de la; di Cosimo, S.; Rubio, I. T.; Harbeck, N.; Baselga, J. und Cortés, J. (2016): Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study. In: Cancer Research, Bd. 76

Liedtke, C.; Gluz, O.; Heinisch, F.; Feuerhake, F.; Kreipe, H. H.; Clemens, M.; Nuding, B.; Kraemer, S.; Reimer, T.; Svedman, C.; Shak, S.; Nitz, U.; Kates, R. E.; Harbeck, N. und Christgen, M. (2016): Association of TILs with clinical parameters, recurrence score, and prognosis in patients with early HER2-negative breast cancer (BC) A translational analysis of the prospective WSG planB trial. In: Cancer Research, Bd. 76

Schwentner, L.; Harbeck, N.; Singer, S.; Eichler, M.; Rack, B.; Forstbauer, H.; Wischnik, A.; Scholz, C.; Fink, V.; Huober, J.; Fried, T.; Weissenbacher, T.; Härtl, K.; Kiechle, M. und Janni, W. (2016): Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer Results from the prospective multi-center randomized Adebar trial. In: Cancer Research, Bd. 76

Harbeck, N.; Zbarskaya, I.; Lipatov, O.; Frolova, M.; Udovitsa, D.; Topuzov, E.; Ganea-Motan, D. E.; Nakov, R.; Singh, P.; Rudy, A. und Blackwell, K. (2016): A randomized, double-blind trial to compare the efficacy and safety of proposed biosimilar pegfilgrastim (LA-EP2006) with reference pegfilgrastim in patients with breast cancer (PROTECT1). In: Cancer Research, Bd. 76

Hadji, P.; Coleman, R. E.; Wilson, C.; Powles, T. J.; Clezardin, P.; Aapro, M.; Costa, L.; Body, J.-J.; Markopoulos, C.; Santini, D.; Diel, I.; Di Leo, A.; Cameron, D.; Dodwell, D.; Smith, I.; Gnant, M.; Gray, R.; Harbeck, N.; Thurlimann, B.; Untch, M.; Cortes, J.; Martin, M.; Albert, U.-S.; Conte, P.-F.; Ejlertsen, B.; Bergh, J.; Kaufmann, M. und Holen, I. (2016): Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. In: Annals of Oncology, Bd. 27, Nr. 3: S. 379-390

Baselga, J.; Cortés, J.; De Laurentiis, M.; Diéras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y.-H.; Jacot, W.; Krop, I. E. und Verma, S. (2016): SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors. In: Cancer Research, Bd. 76

Schönecker, S.; Walter, F.; Freislederer, P.; Marisch, C.; Scheithauer, H.; Harbeck, N.; Corradini, S. und Belka, C. (2016): Treatment planning and evaluation of gated radiotherapy in left-sided breast cancer patients using the Catalyst (TM)/Sentinel (TM) system for deep inspiration breath-hold (DIBH). In: Radiation Oncology 11:143 [PDF, 2MB]

Gluz, O.; Liedtke, C.; Huober, J.; Peyro-Saint-Paul, H.; Kates, R. E.; Kreipe, H. H.; Hartmann, A.; Pelz, E.; Erber, R.; Mohrmann, S.; Möbus, V.; Augustin, D.; Hoffmann, G.; Thomssen, C.; Jänicke, F.; Kiechle, M.; Wallwiener, D.; Kuhn, W.; Nitz, U. und Harbeck, N. (2016): Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2-early breast cancer: WSG-AGO EC-Doc Trial. In: Annals of Oncology, Bd. 27, Nr. 6: S. 1035-1040

Liedtke, C.; Gluz, O.; Nitz, U.; Christgen, M.; Sotlar, K.; Grischke, E.-M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Linder, C.; Kümmel, S.; Clemens, M.; Potenberg, J.; Peter, S.; Kohls, A.; Pelz, E.; Kates, R. E.; Würstlein, R.; Kreipe, H. und Harbeck, N. (2016): Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. In: Oncology Research and Treatment, Bd. 39: S. 53

Schinköthe, T.; Harbeck, N.; Overkamp, F.; Weislau, M.; Würstlein, R. und Gieseler, F. (2016): CANKADO: First open eHealth platform for Oncology. In: Oncology Research and Treatment, Bd. 39: S. 23

Wuerstlein, R.; Prat, A.; Ortega, V; Pare, L.; Galvan, P.; Nuciforo, P.; Oliverira, M.; Amillano, K.; Lopez, R.; Lluch, A.; Morales, S.; Gonzales, R.; Manso, L.; Martinez, J.; Llombart, A.; Pena, L. de la; Di Cosimo, S.; Rubio, I; Baselga, J.; Cortes, J. und Harbeck, N. (2016): Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer. In: Oncology Research and Treatment, Bd. 39: S. 182-183

Kolben, Thomas; Augustine, D.; Armbrust, R.; Kolben, T. M.; Degenhardt, T.; Burgmann, M.; Goess, C.; Ditsch, N.; Kates, R.; Harbeck, N. und Wuerstlein, R. (2016): Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer. In: Breast Cancer Research and Treatment, Bd. 155, Nr. 1: S. 109-115

Gluz, O.; Nitz, U.; Christgen, M.; Kates, R.; Clemens, M.; Kraemer, S.; Nuding, B.; Aktas, B.; Kuemmel, S.; Reimer, T.; Lorenz-Salehi, F.; Krabisch, P.; Just, M.; Augustin, D.; Liedtke, C.; Svedman, C.; Shak, S.; Wuerstlein, R.; Kreipe, H. und Harbeck, N. (2016): Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer. In: European Journal of Cancer, Bd. 57: S6-S6

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Ghali, N.; Orujov, E.; Kates, R. E.; Cowens, W.; Hornberger, J.; Pelz, E. und Harbeck, N. (2016): The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. In: Current Medical Research and Opinion, Bd. 32, Nr. 7: S. 1217-1224

Harbeck, N.; Gascon, P.; Jones, C. M.; Nixon, A.; Krendyukov, A.; Nakov, R.; Mo, M. und Blackwell, K. L. (2016): Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer receiving myelotoxic chemotherapy: Pooled subgroup analysis of two randomized trials. In: Annals of Oncology, Bd. 27

Schindler, F.; Schinkoethe, T.; Kirkovits, T.; Drewes, C.; Harbeck, N. und Wuerstlein, R. (2016): eHealth acceptance in breast cancer care. In: Oncology Research and Treatment, Bd. 39: S. 52-53

Wuerstlein, R.; Burgmann, M.; Lotz, A.; Schlager, V.; Engel, J.; Harbeck, N. und Hermelink, K. (2016): Life satisfaction and life quality in the elderly patient with breast cancer. In: Oncology Research and Treatment, Bd. 39: S. 51

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Hofmann, D.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Morel, P.; Cowens, W.; Hornberger, A.; Kates, R. E.; Pelz, E. und Harbeck, N. (2016): Prosigna® results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study. In: Oncology Research and Treatment, Bd. 39: S. 49

Burgmann, M.; Hermelink, K.; Farr, A.; Meegen, F. van; Engel, J.; Harbeck, N. und Wuerstlein, R. (2016): Young breast cancer survivors-reproductive concerns, life satisfaction and cancer-specific distress. In: Oncology Research and Treatment, Bd. 39: S. 48

Baselga, J.; Cortes Castan, J.; De Laurentiis, M.; Dieras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y.-H.; Jacot, W.; Krop, I. E. und Verma, S. (2016): SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours. In: Annals of Oncology, Bd. 27

Rugo, H.; Dieras, V.; Gelmon, K. A.; Finn, R.; Slamon, D.; Miguel, M.; Neven, P.; Ettl, J.; Shparyk, Y.; Mori, A.; Lu, D. R.; Bhattacharyya, H.; Bartlett, C. H.; Iyer, S.; Johnston, S. und Harbeck, N. (2016): Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naive postmenopausal patients with ER+HER2-metastatic breast cancer (MBC): results from PALOMA-2. In: Annals of Oncology, Bd. 27

Loibl, S.; Demichele, A.; Turner, N. M.; Cristofanilli, M.; Loi, S.; Verma, S.; Bhattacharyya, H.; Ke, Z.; Giorgetti, C.; Bartlett, C. H.; Iyer, S.; Colleoni, M.; Masuda, N.; Im, S.-A. und Harbeck, N. (2016): Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2-metastatic breast cancer. In: Annals of Oncology, Bd. 27

Janni, W.; Harbeck, N.; Rack, B.; Augustin, D.; Jückstock, J.; Wischnik, A.; Annecke, K.; Scholz, C.; Huober, J.; Zwingers, T.; Friedl, T. W. P. und Kiechle, M. (2016): Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. In: British Journal of Cancer, Bd. 114, Nr. 8: S. 863-871

Corradini, S.; Niyazi, M.; Niemoeller, O. M.; Li, M.; Roeder, F.; Eckel, Renate; Schubert-Fritschle, Gabriele; Scheithauer, H. R.; Harbeck, N.; Engel, Jutta und Belka, Claus (2015): Adjuvant radiotherapy after breast conserving surgery - a comparative effectiveness research study. In: Radiotherapy and Oncology, Bd. 114, Nr. 1: S. 28-34

Kolben, T.; Schwarz, T. M.; Goess, C.; Blume, C.; Degenhardt, T.; Engel, Jutta; Wuerstlein, R.; Ditsch, N.; Harbeck, N. und Kahlert, S. (2015): Surgical management of ipsilateral breast tumor recurrence. In: International Journal of Surgery, Bd. 23, Nr. Pt A: S. 141-146

Kolben, T.; Harbeck, N.; Wuerstlein, R.; Schubert-Fritschle, Gabriele; Bauerfeind, I.; Schrodi, Simone und Engel, Jutta (2015): Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry. In: Breast, Bd. 24, Nr. 1: S. 24-31

Diese Liste wurde am Sat Apr 20 21:48:24 2024 CEST erstellt.

Exportieren als	RSS 1.0 RSS 2.0